Prevention of Cardiovascular Disease in Chronic Kidney Disease Patients

Seminars in Nephrology

Volumn 29, Issue 1, 2009, Pages 24-29

  Wanner, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

arteriosclerosis; Atherosclerosis; dialysis; dyslipidemia; risk factors; statins

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; VITAMIN D;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; KIDNEY FUNCTION; MORTALITY; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SMOKING; SODIUM RESTRICTION;

ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 58049128901     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2008.10.004     Document Type: Article

References (38)

1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
2. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 Suppl 3 (1998) S112-S119
3. Wanner C., Krane V., März W., Olschewski M., Mann J.F., Ruf G., et al., German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
4. Keith D.S., Nichols G.A., Gullion C.M., Brown J.B., and Smith D.H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164 (2004) 659-663
5. Herzog C.A., Mangrum J.M., and Passman R. Sudden cardiac death and dialysis patients. Semin Dial 21 (2008) 3000-3007
6. Gross M.-L., and Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia-beyond coronary heart disease. Semin Dial 21 (2008) 308-318
7. Ritz E., and Wanner C. The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol 3 (2008) 920-929
8. Kronenberg F., Kuen E., Ritz E., Junker R., König P., Kraatz G., et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11 (2000) 105-115
9. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18 (2007) 2600-2608
10. Boes E., Fliser D., Ritz E., König P., Lhotta K., Mann J.F., et al. Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 17 (2006) 528-536
11. Fliser D., Kronenberg F., Kielstein J.T., Morath C., Bode-Böger S.M., Haller H., et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 16 (2005) 2456-2461
12. Sturm G., Kollerits B., Neyer U., Ritz E., Kronenberg F., and MMKD Study Group. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease?. The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol 43 (2008) 347-352
13. Spanaus K.S., Kronenberg F., Ritz E., Schlapbach R., Fliser D., Hersberger M., et al., Mild-to-Moderate Kidney Disease Study Group. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem 53 (2007) 1264-1272
14. Kollerits B., Fliser D., Heid I.M., Ritz E., Kronenberg F., and MMKD Study Group. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 71 (2007) 1279-1286
15. Kjekshus J., Apetrei E., Barrios V., Böhm M., Cleland J.G., Cornel J.H., et al., CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
16. Jamison R.L., Hartigan P., Kaufman J.S., Goldfarb D.S., Warren S.R., Guarino P.D., et al., Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298 (2007) 1163-1170
17. Boaz M., Smetana S., Weinstein T., Matas Z., Gafter U., Iaina A., et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356 (2000) 1213-1218
18. Tepel M., van der Giet M., Statz M., Jankowski J., and Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107 (2003) 992-995
19. Cice G., Ferrara L., D'Andrea A., D'Isa S., Di Benedetto A., Cittadini A., et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41 (2003) 1438-1444
20. Zannad F., Kessler M., Lehert P., Grünfeld J.P., Thuilliez C., Leizorovicz A., et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70 (2006) 1318-1324
21. Hyre A.D., Fox C.S., Astor B.C., Cohen B.C., Cohen A.J., and Muntner P. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis 49 (2007) 37-45
22. Tonelli M. Should CKD be a coronary heart disease risk equivalent?. Am J Kidney Dis 49 (2007) 8-11
23. Sanfelippo M.L., Swenson R.S., and Reaven G.M. Reduction of plasma triglycerides by diet in subjects with chronic renal failure. Kidney Int 11 (1977) 54-61
24. Ando M., Sanaka T., and Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 10 (1999) 2177-2184
25. Keane W.F., Kasiske B.L., O'Donnell M.P., and Kim Y. The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis 17 Suppl 1 (1991) 38-42
26. Sandhu S., Wiebe N., Fried L.F., and Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17 (2006) 2006-2016
27. Tonelli M., Isles C., Curhan G.C., Tonkin A., Pfeffer M.A., Shepherd J., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 (2004) 1557-1563
28. Tonelli M., Isles C., Craven T., Tonkin A., Pfeffer M.A., Shepherd J., et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112 (2005) 171-178
29. Holdaas H., Fellström B., Jardine A.G., Holme I., Nyberg G., Fauchald P., et al., Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
30. Holdaas H., Fellström B., Cole E., Nyberg G., Olsson A.G., Pedersen T.R., et al., Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 5 (2005) 2929-2936
31. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al., ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
32. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
33. Tonelli M., Keech A., Shepherd J., Sacks F., Tonkin A., Packard C., et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 16 (2005) 3748-3754
34. Fathi R., Isbel N., Short L., Haluska B., Johnson D., and Marwick T.H. The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis 43 (2004) 45-52
35. Schwarz U., Buzello M., Ritz E., Stein G., Raabe G., Wiest G., et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15 (2000) 218-223
36. Colivicchi F., Bassi A., Santini M., and Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 38 (2007) 2652-2657
37. Fellström B., Holdaas H., Jardine A.G., Rose H., Schmieder R., Wilpshaar W., et al., AURORA Study Group. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res 30 (2007) 314-322
38. Baigent C., and Landray M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 84 (2003) S207-S210